Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)

Fontaine, Christel; Renard, Vincent; Van den Bulck, Heidi; Vuylsteke, Peter; Glorieux, Philippe; Dopchie, Catherine; Decoster, Lore; Awada, Ahmad; Wildiers, Hans; De Brakeleer, Sylvie; Teugels, Erik; De Greve, Jacques

doi:10.1158/1538-7445.SABCS19-P1-10-05

Cancer Research

Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)

Author:

Fontaine, Christel

Renard, Vincent ; Van den Bulck, Heidi ; Vuylsteke, Peter ; Glorieux, Philippe ; Dopchie, Catherine ; Decoster, Lore ; Awada, Ahmad ; Wildiers, Hans ; De Brakeleer, Sylvie ; Teugels, Erik ; De Greve, Jacques

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3101 Biochemistry and cell biology, 3211 Oncology and carcinogenesis

Cancer Research Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)

Author:

Keywords:

About us

Our services

Our solutions

Cancer Research

Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)